Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...
March 19, 2026 06:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...
March 12, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
March 09, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
February 23, 2026 08:00 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
January 13, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

DURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
January 05, 2026 07:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in...
December 23, 2025 17:57 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
December 04, 2025 07:00 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new...
December 02, 2025 08:00 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...